Please login to the form below

Not currently logged in
Email:
Password:

neurodegenerative

This page shows the latest neurodegenerative news and features for those working in and with pharma, biotech and healthcare.

Daily brief: Novartis spends big on ezcema,

Daily brief: Novartis spends big on ezcema,

Funds raised from the IPO will enable MeiraGTx to progress its product candidates to treat inherited rare eye diseases, xerostomia (‘dry mouth’) and neurodegenerative diseases.

Latest news

More from news
Approximately 7 fully matching, plus 115 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Takeda moves in neurodegenerative diseases and stem cell therapy. Meanwhile Takeda, ranked 4. ... Option, licence. 223. Karyopharm Therapeutics/ Biogen. Oral SINE compound KPT-350 (IND ready) other assets for neurological and neurodegenerative conditions.

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    These deals were mainly early stage deals in the areas of gastroenterology, neurodegenerative diseases and an $830m ($40m upfront) deal with Mersana for rights outside North America to a phase 1

  • Deal Watch December 2016 Deal Watch December 2016

    320. Evotec (Germany). Celgene (US). Discovery collaboration. Induced pluripotent stem cells for neurodegenerative diseases.

  • Deal Watch November 2016 Deal Watch November 2016

    equity investment, 2 year collaboration. 145. Chase Pharmaceuticals/ Allergan. fixed dose combinations for Alzheimer's and other neurodegenerative diseases inc CPC-201 (donepezil).

  • Deal Watch February 2016 Deal Watch February 2016

    The company is developing oral biologics that deliver disease specific amino acid compositions to restore balance in disease pathways in indications such as muscle, neurodegenerative and liver diseases.

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

  • Biogen appoints executive VP, corporate development Biogen appoints executive VP, corporate development

    I'm excited to work with Biogen's innovative and talented team as we work to expand the company's portfolio of therapies for people living with serious neurodegenerative diseases.”.

  • Prevail Therapeutics adds to its board of directors Prevail Therapeutics adds to its board of directors

    Prevail Therapeutics, a biotechnology company focused on the development of gene therapies for patients with neurodegenerative diseases, has strengthened its board of directors with the addition of Francois Nader. ... The Prevail team has already made

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    Asceneuron appoints chief medical officer. Novartis’ Michael Ryan joins the neurodegenerative diseases specialist. ... He joins the neurodegenerative diseases specialist from Novartis, where he had served a s vice president of its neuroscience

  • UK Dementia Research Institute names director UK Dementia Research Institute names director

    Prof De Strooper is currently a professor of molecular medicine at the University of Leuven and leads its laboratory for the research of neurodegenerative diseases.

  • Pfizer appoints chief scientific officer Pfizer appoints chief scientific officer

    Dr Mikael Dolsten, president of worldwide research and development at Pfizer, said: “ Dr Isacson's deep expertise in neurodegenerative disorders is well-aligned with our work in Alzheimer's and

More from appointments
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest from PMHub

  • Alzheimer's and Brain Awareness Month

    AD is a neurodegenerative disease, meaning that its symptoms are generally mild at the start, but become progressively worse over time, eventually interfering with the everyday life of those affected.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics